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Background: Renal function improves early (1 month) after left ventricular assist device (LVAD) implantation. However preliminary data has 
suggested a later decline. We sought to determine the occurrence and predictors associated with late decline in renal function up to 1 year after 
LVAD implantation.
Methods: A retrospective single center analysis of 62 consecutive patients implanted with a HeartMate II continuous flow LVAD with available 
calculated glomerular filtration rate (GFR, ml/min/1.73m2) one year after implant. GFR was assessed on admission and 1, 3, 6 and 12 months 
after implantation. To define predictors for late decline in GFR we examined clinical variables and their association with change in GFR from 1 to 12 
months after implant.
Results: GFR at admission was (54.5±19.5), increased to (66.4±22.3) pre-operatively and to (81.3±28.3) one month after LVAD implantation. 
Subsequently at 3 months GFR declined to (75.9±23.9), at 6 months to (70.1±21.8) and 1 year after implant to (63.9±17.7). GFR at 1 year was 
comparable (p=0.257) to pre-operative and significantly lower (p<0.0001) than GFR 1, 3 and 6 months after implant but was still higher than GFR 
at admission (p<0.0001). Significant pre-operative univariate predictors for decline in renal function from 1 month to 12 months after implant 
included: intra-aortic balloon pump use (p<0.001), high heart rate (p=0.023), bilirubin (p=0.002), LDH (p=0.005) RA pressure (p=0.003) higher 1 
month GFR (p<0.001) and improved GFR from admission to 1 month (p<0.001). Predictors for less decline in GFR included prolonged RV ejection 
time (p=0.015), Stroke index (p=0.004) and cardiac index (p=0.038). Multivariate analysis indicated higher preoperative LDH (slope of -0.008 units 
per unit decline, CI -0.002 to -0.01 p=0.002) and higher 1 month GFR (slope of -0.5 units per unit decline, CI -0.4 to -0.6 p<0.001) as independent 
predictors.
Conclusions: Despite an initial improvement in GFR after LVAD implantation early gains in renal function are not sustained in many patients 
receiving LVAD therapy, this study for the first time identifies subgroups most likely to derive maximal benefit. 
